This House resolution expresses support for designating July 16, 2025, as "Glioblastoma Awareness Day." The resolution describes glioblastoma as the most common malignant brain tumor (about half of primary malignant brain tumors) and one of the most aggressive and deadly. It cites estimates that more than 13,000 Americans will be diagnosed with glioblastoma in 2025 and that more than 10,000 people in the United States will die from it each year. The resolution quotes a 5-year survival rate of 6.9 percent and a median survival of about 8 months. It notes that glioblastoma is hard to treat, that there are no screening or early detection methods, and that few drugs and one device have been FDA-approved specifically for glioblastoma since the 1920s. The text highlights changes in molecular characteristics in 2021 that make biomarker testing important and references the National Cancer Institute's Glioblastoma Therapeutics Network (GTN), established in 2020, as a research resource. The resolution expresses support for the designation, encourages public awareness, honors people affected by glioblastoma, supports development of better treatments, recognizes molecular biomarker testing, urges collaborative research, and encourages continued investments in research including through the GTN.
No publicly available information. The resolution does not specify funding levels or authorize spending.
Supporters say there is a need for greater public awareness about the urgent medical needs of glioblastoma patients and opportunities for research. The resolution highlights the disease's low survival rates, the limited number of approved treatments, the importance of molecular biomarker testing after 2021 changes, and the role of research networks such as the GTN. It calls for honoring patients and families and for collaborative efforts to advance treatments and improve quality of life.
No publicly available information.